neuroFit

An in vivo experimental model used to assess cognitive function in mice or rats by measuring spontaneous, continuous, and sustained alternation behavior in a T-maze setup.

A method implemented to evaluate the spatial exploratory performance in mice.

A behavioral test to evaluate cognitive deficit by measuring reduction in alternation, useful for screening cognitive enhancing compounds.

Mouse model using Light-Dark test to evaluate anxiety status, including a variant mimicking CCK-4-induced panic anxiety. Used for screening anxiolytic compounds and phenotyping.

A test based on the conflict between rodents' innate aversion to brightly illuminated areas and spontaneous exploratory activity, used to assess anxiety.

A rodent behavioral test evaluating working memory based on spontaneous exploration of novel and familiar objects, used for screening compounds with memory enhancing properties.

The object recognition task in rodents is considered a test for evaluating working memory in rodents based on spontaneous exploration of novel and familiar objects.

A rodent behavioral test used to assess short-term and/or long-term memory by measuring latency to enter a dark compartment paired with an aversive stimulus (mild foot shock).

The Passive Avoidance is a fear-aggravated test used to assess short- or long-term memory. The test requires rodents to act contrary to their innate behaviour.

The elevated plus maze (EPM) test evaluates relative anxiety status of mice or rats based on their conflict between exploring novel environments and avoiding open, brightly lit areas.

A test based on the conflict between rodents' innate tendencies to explore novel environments and avoid open and brightly lit areas, used to assess anxiety.

An in vivo animal model used to study anxiety, involving the Elevated Plus Maze paradigm with Cholecystokinin tetrapeptide (CCK-4) to induce anxiety-like behavior.

Preclinical Contract Research Organization (CRO) services specializing in CNS and PNS disorders, offering validated in vivo and in vitro disease and safety models for drug screening.

Models developed for several neurological diseases including Alzheimer’s disease, Parkinson's disease, epilepsy, neuropathic pain and peripheral neuropathies.

Neurocellular models and assays for evaluating neurotoxicity, neuroprotection, and neurotrophic activity of test compounds, including rat primary cultures and co-cultures.

A functional neuronal assay developed by NEUROFIT that accumulates extracellular amyloid beta (Aβ) to assess the efficiency of Aβ lowering drugs such as BACE inhibitors, and provides information about potential safety or neurotoxicity of the tested drug.

Animal model of Alzheimer's disease using aged mice that naturally develop cognitive deficits and Alzheimer's symptoms, representing the human disease for testing multiple pathways therapeutics.

Amyloid-β i.c.v injection induces learning deficits and a dysfunction of the cholinergic system, mimicking the cognitive deficit associated with Alzheimer’s disease. Assessed using the passive avoidance test.

An in vitro assay to evaluate neurotrophic activity, useful for screening compounds affecting neuronal growth and survival.

In vitro cellular models for Alzheimer's disease research including viability and survival tests and basal Amyloid β production assays.

A rat model of Parkinson's disease using 6-hydroxydopamine (6-OHDA) to produce striatal dopamine depletion and motor deficits, used for compound testing and neuroprotection studies.

Neurotrophic and cognitive-enhancing drug evaluated by NEUROFIT in various in vivo and in vitro models for CNS and PNS disorders.

An in vivo rat model of peripheral neuropathy induced by streptozotocin administration causing rapid and persistent hyperglycaemia, used to study diabetic neuropathy characterized by reduced nerve conduction and loss of sensation due to skin denervation.

An in vitro model to evaluate neurotrophic activity and therapeutics for neuromuscular diseases by assessing the neuroprotective or neurotrophic effect of compounds on spinal cord injury.

An in vitro test exploiting the natural tendency of cells to die in culture to assess the neuroprotective properties of compounds, adaptable to various cell types depending on the targeted pathology.

A behavioral test where animals placed in a container filled with water show periods of increased swimming activity and periods of relative immobility to assess depression-like behavior.

The hot-plate test measures thermal pain reflexes in animals placed on a heated plate, characterized by paw withdrawal or licking.

Rodent model of Alzheimer's disease using Methyllycaconitine, an alpha-7 nicotinic acetylcholine receptor specific antagonist with brain penetrance, to induce cognitive deficit.

The paw pressure test applies increasing mechanical pressure on the animal paw inducing pain leading to an escape reaction.

Primary culture of adult neurons reflecting the broad diversity of mature neuronal population, suitable for neurotrophic, neuroprotective, or neurotoxic compound assessment.

A cellular co-culture model measuring surface area of innervated muscle fibers and innervation rate for ALS research.

A focused cellular model to study direct neuronal responses to stimuli, useful for assessing neurotrophic, neuroprotective, or neurotoxic properties of compounds.

A comprehensive list of rodent disease models for assessing drug candidate efficiency with quantitative behavioral measurements.

A cellular model mimicking in vivo nerve axon/neuron-glia interaction, allowing study of Schwann cells' involvement in sensory neuron survival.

A disease model for Multiple Sclerosis in rats that mimics the remittance and relapse phases seen in MS patients, useful for evaluating the effect of compounds on disease relapse.

A translational test implemented by Neurofit to evaluate the neuroprotective effect of compounds by stimulating a nerve fiber and monitoring the muscle response, commonly altered in peripheral neuropathies.

Animal model of nerve / axonal regeneration used to study peripheral nerve regeneration and evaluate therapeutic interventions to boost axonal regeneration. Monitors gait, nerve function, and axon morphology correlates for compound testing.

A test measuring imbalance weight distribution in freely moving animals to assess pain or discomfort.

Rodent model of panic anxiety induced by cholecystokinin tetrapeptide (CCK-4) or Yohimbine, validated using the Elevated Plus Maze test (EPM) in rats. Used for testing anxiolytic and anti-panic drugs.

Cellular model for Alzheimer's disease research involving amyloid beta-induced toxicity to study neurodegeneration.

In vitro neuronal culture intoxication model with Aβ peptides to study cell death mechanisms and evaluate neuroprotective drug candidates for Alzheimer's disease.

T-maze based test to evaluate cognitive and memory performance by measuring spontaneous and continuous alternation in rodents.

Characterization and evaluation of chemodenervation agents in rats and mice by measuring compound muscular action potential (CMAP) after motor nerve stimulation.

An instrumented floor-cage combined with video recording to evaluate spontaneous pain in freely moving rodents, assessing neuromuscular activity and weight distribution imbalance.

Model for mild cognitive impairment and dementia testing using aged mice to evaluate cognitive enhancers and therapies for Alzheimer's disease.

Cellular model using induced pluripotent stem cell-derived neurons for Alzheimer's disease research.

An animal model used to measure neuromuscular junction function and fiber morphometry, assessing electrophysiological parameters such as sensory nerve conduction velocity (SNCV) and compound muscle action potential (CMAP) to evaluate neuroprotective and neuro-regenerative effects of compounds.

Rats walk across an elevated 2.5m long beam graduated every 50cm. Successful walking is scored with 1 point, misplacement with -1.

A rodent model proposed by NEUROFIT to assess the efficiency of compounds for neuropathic pain related to peripheral neuropathy caused by diabetes.

Behavioral tests and animal models to assess anxiolytic, antidepressant, antipsychotic, or procognitive effects of compounds, mimicking clinical symptoms.

Assay to evaluate neuroprotective effects of compounds against amyloid beta-induced damage.

Functional neuronal assay measuring extracellular Aβ accumulation to assess efficiency of Aβ lowering drugs and potential neurotoxicity.

A cellular model assay measuring neurite outgrowth in spinal motor neurons for ALS research.

Rodent model of schizophrenia characterized by D-amphetamine induced hyperactivity, used to study cognitive disturbances and hyperactivity related to schizophrenia.

An in vivo mouse model where inflammation is induced by a single administration of a non-septic dose of LPS, used to study inflammation-induced cognitive decline and test drug effects.

A validated in vivo mouse model recreating PCP-induced cognitive behavioral impairment to support drug discovery for schizophrenia-related cognitive deficits.

The rotarod is a performance test based on a rotating rod with forced motor activity being applied.

A rat model using PCP-induced cognitive impairment as a surrogate for cognitive impairment in schizophrenia, with proof of concept data using nicotine to improve memory deficit.

The Open-Field test assays general locomotor activity levels in rodents.

In-vivo models for inflammation, contact allergic and autoimmune diseases for therapeutic screening of immunomodulators, anti-inflammatory, and immuno-suppressor drugs.

A functional in vitro model of motor unit coculture using rat spinal motor neurons and human muscle to evaluate neurotrophic activity and therapeutics for neuromuscular diseases.

An automated formalin test used as an animal model to study neuropathic pain mechanisms and evaluate analgesic compounds.

An animal model of cognitive deficit in which ADHD medication drugs (methylphenidate, amphetamine and atomoxetine) fully restore cognitive performance. The model implements pharmacological alteration of central cholinergic system implicated in ADHD pathology.

A test implemented by NEUROFIT to evaluate the neuroprotective properties of compounds by measuring sensory nerve conduction velocity, used in the diagnosis of nerve damage or dysfunction.

The marble burying test is used to record the number of marbles buried by mice placed in a novel environment. It has predictive value for anti-depressant and/or anxiolytic drugs and assesses repetitive/persistent behavior relevant to OCD and ASD.

Assay to test inhibition of amyloid beta production by the compound BMS-299897.

The integrity of muscle function is assessed by the time taken by the mouse to catch a wire in the hindpaws whilst hanging from its forepaws.

An animal model of cognitive deficit induced by scopolamine to test the ability of compounds to reverse ADHD-related cognitive symptoms.

Oxazolone is used to induce allergic contact dermatitis in rats, resulting in a type I cytokine response, useful for identification of anti-inflammatory and immuno-modulating drugs.

A thermal hyperalgesia test where the animal's tail is subjected to a heat source, causing spontaneous tail removal when uncomfortable.

An animal model used for studying Amyotrophic Lateral Sclerosis (ALS) focusing on neuromuscular junction and muscle fiber morphology.

Forelimb contacts with the wall of an open-top, clear plastic cylinder while rearing are counted during 2 min period to calculate the percentage use of the affected forelimb as an index of motor function.

Electromyography (EMG) testing service to study the in-vivo myorelaxant effects of compounds, including anti-wrinkle agents.

Delayed Type Hypersensitivity is induced in female Lewis rats by a subcutaneous injection of an emulsion of ovalbumin/complete Freund's adjuvant, followed by an ovalbumin challenge in the pinna ear to model allergic contact dermatitis.

Imbalance weight distribution in freely moving animal.